Trials / Completed
CompletedNCT05828745
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects With Chronic Hepatitis B
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of CB06-036 in Subjects With Chronic Hepatitis B
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Shanghai Zhimeng Biopharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
CB06-036 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Chronic Hepatitis B.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CB06-036 | CB06-036 capsule |
| DRUG | Placebo | Placebo capsule |
Timeline
- Start date
- 2024-04-22
- Primary completion
- 2025-02-18
- Completion
- 2025-02-18
- First posted
- 2023-04-25
- Last updated
- 2025-05-21
Locations
2 sites across 2 countries: China, New Zealand
Source: ClinicalTrials.gov record NCT05828745. Inclusion in this directory is not an endorsement.